Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors

Jeffrey R. Infante,Vicki L. Keedy,Suzanne F. Jones,William C. Zamboni,Emily Chan,Johanna C. Bendell,Wooin Lee,Huali Wu,Satoshi Ikeda,Hiroshi Kodaira,Mace L. Rothenberg,Howard A. Burris

Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors

2012

Jeffrey R. Infante
Vicki L. Keedy
Suzanne F. Jones
William C. Zamboni
Emily Chan
Johanna C. Bendell
Wooin Lee
Huali Wu
Satoshi Ikeda
Hiroshi Kodaira
Mace L. Rothenberg
Howard A. Burris

Purpose IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL-305 and established the maximum tolerated dose and recommended phase II dose (RP2D).

Keywords:

Pegylated Liposomal Irinotecan
Liposome
Pharmacology
Irinotecan
Maximum tolerated dose
Medicine
Pharmacokinetics
pharmacology toxicology
in patient
safety profile
pegylated liposomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations